The Eli Lilly and Co.’s triple-mechanism diabetes drug Mounjaro, or retatrutide, achieved an average weight reduction of 58 pounds, or 24.2%, after 48 weeks of therapy according to trial results presented at an American Diabetes Association conference and published in The New England Journal of Medicine. FDA approval of the drug for weight loss is pending, and the manufacturer said a Phase 3 trial is planned.
Full Story: MedCity News (6/27)